GO
Loading...

Genentech Warns of Stroke Risk for Blindness Drug Users

Genentech has sent a letter alerting eye doctors to the risk of stroke from Lucentis, its drug for treating age-related macular degeneration, a spokeswoman said.

The letter was a "proactive effort" to advise doctors that an interim analysis of a large 5,000-patient trial shows that 1.2% of patients given a 0.5-milligram dose of the drug suffered a stroke, compared with 0.3% of patients given a 0.3-mg dose, said spokeswoman Dawn Kalmar.

She said the findings mirror those shown in previous trials of Lucentis, which was approved by the U.S. Food and Drug Administration last year.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video

  • Qualcomm is reporting EPS beat of $1.34 adjusted on revenue beat of $7.10 billion, with CNBC's Jon Fortt.

  • President Obama has dropped his controversial proposal to tax 529 plans, but as CNBC's Sharon Epperson reports, the ability to withdraw tax-fee funds for higher education isn't the only reason these plans are an attractive vehicle for millions of families to save for college.

  • "The Playboy of Indiana" Timothy Durham dates exotic models, owns 80 sports cars, all bankrolled by a $200 million fraud.